Cargando…

Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls

BACKGROUND: Evidence suggests that MDM2 T309G polymorphism may be a risk factor for several cancers. Increasing investigations have been conducted on the association of MDM2 T309G polymorphisms with lung cancer risk and have yielded conflicting results. Previous meta-analyses on this issue have repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Wenlei, Zhang, Liang, Zhu, Bo, Ling, Junjun, Chen, Zhengtang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402389/
https://www.ncbi.nlm.nih.gov/pubmed/22844496
http://dx.doi.org/10.1371/journal.pone.0041546
_version_ 1782238737174888448
author Zhuo, Wenlei
Zhang, Liang
Zhu, Bo
Ling, Junjun
Chen, Zhengtang
author_facet Zhuo, Wenlei
Zhang, Liang
Zhu, Bo
Ling, Junjun
Chen, Zhengtang
author_sort Zhuo, Wenlei
collection PubMed
description BACKGROUND: Evidence suggests that MDM2 T309G polymorphism may be a risk factor for several cancers. Increasing investigations have been conducted on the association of MDM2 T309G polymorphisms with lung cancer risk and have yielded conflicting results. Previous meta-analyses on this issue have reported inconclusive data. The aim of the present study was to derive a more precise estimation of the relationship. METHODS AND FINDINGS: Updated meta-analyses examining the association between MDM2 T309G polymorphism and lung cancer risk were performed. Separate analyses on ethnicity, smoking status, histological types and gender as well as source of controls were also implemented. Eligible studies were identified for the period up to Feb 2012. Lastly, ten publications including eleven case-control studies were selected for analysis. The overall data failed to indicate a significant association between MDM2 T309G polymorphism and lung cancer risk (GG vs TT OR = 1.14; 95%CI = 0.95−1.37; dominant model: OR = 1.05; 95%CI = 0.92−1.19; recessive model: OR = 1.12; 95%CI = 0.99−1.27). In a subgroup analysis by smoking status, increased lung cancer risk was shown among never-smokers (GG vs TT: OR = 1.76; 95%CI = 1.36−2.29; dominant model: OR = 1.48; 95%CI = 1.22−1.81; recessive model: OR = 1.37; 95%CI = 1.11−1.69). In subgroup analysis by gender, elevated risk was presented among women under a recessive model (OR = 1.29; 95%CI = 1.04−1.59). In the subgroup analysis by ethnicity, histological types and source of controls, no marked associations were observed. CONCLUSIONS: Compared to the previous meta-analyses, the results of this study confirmed that MDM2 T309G polymorphism might be a risk factor for lung cancer among never-smokers. However, the data failed to suggest a marked association between the G allele of MDM2 T309G and lung cancer risk among Asians. More interestingly, subgroup analysis by gender indicated that homozygous GG alleles might raise lung cancer risk among females.
format Online
Article
Text
id pubmed-3402389
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34023892012-07-27 Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls Zhuo, Wenlei Zhang, Liang Zhu, Bo Ling, Junjun Chen, Zhengtang PLoS One Research Article BACKGROUND: Evidence suggests that MDM2 T309G polymorphism may be a risk factor for several cancers. Increasing investigations have been conducted on the association of MDM2 T309G polymorphisms with lung cancer risk and have yielded conflicting results. Previous meta-analyses on this issue have reported inconclusive data. The aim of the present study was to derive a more precise estimation of the relationship. METHODS AND FINDINGS: Updated meta-analyses examining the association between MDM2 T309G polymorphism and lung cancer risk were performed. Separate analyses on ethnicity, smoking status, histological types and gender as well as source of controls were also implemented. Eligible studies were identified for the period up to Feb 2012. Lastly, ten publications including eleven case-control studies were selected for analysis. The overall data failed to indicate a significant association between MDM2 T309G polymorphism and lung cancer risk (GG vs TT OR = 1.14; 95%CI = 0.95−1.37; dominant model: OR = 1.05; 95%CI = 0.92−1.19; recessive model: OR = 1.12; 95%CI = 0.99−1.27). In a subgroup analysis by smoking status, increased lung cancer risk was shown among never-smokers (GG vs TT: OR = 1.76; 95%CI = 1.36−2.29; dominant model: OR = 1.48; 95%CI = 1.22−1.81; recessive model: OR = 1.37; 95%CI = 1.11−1.69). In subgroup analysis by gender, elevated risk was presented among women under a recessive model (OR = 1.29; 95%CI = 1.04−1.59). In the subgroup analysis by ethnicity, histological types and source of controls, no marked associations were observed. CONCLUSIONS: Compared to the previous meta-analyses, the results of this study confirmed that MDM2 T309G polymorphism might be a risk factor for lung cancer among never-smokers. However, the data failed to suggest a marked association between the G allele of MDM2 T309G and lung cancer risk among Asians. More interestingly, subgroup analysis by gender indicated that homozygous GG alleles might raise lung cancer risk among females. Public Library of Science 2012-07-23 /pmc/articles/PMC3402389/ /pubmed/22844496 http://dx.doi.org/10.1371/journal.pone.0041546 Text en Zhuo et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhuo, Wenlei
Zhang, Liang
Zhu, Bo
Ling, Junjun
Chen, Zhengtang
Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
title Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
title_full Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
title_fullStr Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
title_full_unstemmed Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
title_short Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
title_sort association of mdm2 snp309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402389/
https://www.ncbi.nlm.nih.gov/pubmed/22844496
http://dx.doi.org/10.1371/journal.pone.0041546
work_keys_str_mv AT zhuowenlei associationofmdm2snp309variationwithlungcancerriskevidencefrom7196casesand8456controls
AT zhangliang associationofmdm2snp309variationwithlungcancerriskevidencefrom7196casesand8456controls
AT zhubo associationofmdm2snp309variationwithlungcancerriskevidencefrom7196casesand8456controls
AT lingjunjun associationofmdm2snp309variationwithlungcancerriskevidencefrom7196casesand8456controls
AT chenzhengtang associationofmdm2snp309variationwithlungcancerriskevidencefrom7196casesand8456controls